Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Metformin (Met) is a widely used antidiabetic drug.
• Previous research suggests Metformin may have anti-cancer properties.
• The specific mechanisms of Metformin's effects on renal cancer cells require further elucidation.

Purpose of the Study:

• To investigate the anti-cancer effects of Metformin on A498 renal cancer cells.
• To elucidate the molecular mechanisms underlying Metformin's action in these cells.
• To evaluate Metformin's potential as a therapeutic agent for renal cancer.

Main Methods:

• A498 cells were treated with varying concentrations and durations of Metformin.
• Cell proliferation, apoptosis, cell cycle, migration, and invasion assays were performed.
• Key protein expressions, including AMP-activated protein kinase, B-cell lymphoma 2, Bcl-2-associated X protein, cyclin D1, and matrix metalloproteinase-2, were analyzed.

Main Results:

• Metformin inhibited A498 cell proliferation in a time- and dose-dependent manner.
• Metformin activated AMP-activated protein kinase and induced apoptosis by downregulating B-cell lymphoma 2 and upregulating Bcl-2-associated X protein.
• Metformin caused G1 cell cycle arrest by decreasing cyclin D1 expression and reduced cell migration and invasion by decreasing matrix metalloproteinase-2.

Conclusions:

• Metformin exhibits significant anti-cancer effects against A498 renal cancer cells in vitro.
• The observed effects include inhibition of proliferation, induction of apoptosis, cell cycle arrest, and suppression of migration and invasion.
• These findings support Metformin's potential as a novel and effective agent for renal cancer treatment.